Alterity Therapeutics Ltd has released a press release.
Alterity Launches ATH434 Phase 2 Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- UK Regulatory Authorisation to Proceed with Phase 2 Trial
- New publication shows ATH434 rescues neurons in MSA model
- Response to ASX Query
- New US Patent for Compounds to Treat Neurodegeneration
- First Regulatory Authorization to Proceed with Phase 2 Trial
Later from Alterity Therapeutics
- Regulatory Approval to Proceed with Phase 2 Trial in Italy
- Alterity receives a $4.1 million R&D Tax Refund
- First Patient dosed in ATH434 Phase 2 Clinical Trial
- ATH434 Phase 2 clinical launched in Europe
- Appendix 4E & Annual Report 2022
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics